Hoechst Hurts
Executive Summary
Jurgen Dormann, the chairman of Hoechst AG, has been trying to make the lumbering German conglomerate into a life-sciences racehorse. But the racehorse may have gotten away from him. In February, open revolt broke out within the German R&D group after an announcement that 600 positions were being cut.You may also be interested in...
WHO To Clean Up Data Integrity Failings
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
Newron Not Seeing Sarizotan STARS Yet
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
Warning Letter Roundup & Recap – 10 December 2019
No device-related warning letters were released by the US FDA the week of 10 December.
Need a specific report? 1000+ reports available
Buy Reports